Roche Holding AG (SWX:ROP)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 265.96B +28.4% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 20.81 |
| Forward PE | 16.26 |
| Dividend | 9.80 (2.94%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 713,283 |
| Open | 332.00 |
| Previous Close | 333.80 |
| Day's Range | 330.50 - 336.90 |
| 52-Week Range | 243.90 - 374.90 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 359.22 (+7.33%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ROP stock is "Buy." The 12-month stock price target is CHF 359.22, which is an increase of 7.33% from the latest price.
News
Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges
Supporting ADLM's focus on collaborative, cross-disciplinary solutions that address laboratory workforce and operational challenges Highlighting innovations in mass spectrometry, next-generation seque...
MaxCyte Signs Multi-Platform Technology License Partnership With Genentech
(RTTNews) - MaxCyte, Inc. (MXCT) has entered into a multi-platform technology license partnership with Genentech, a member of the Roche Group (RHHBY), to advance the development of next-generation cel...
Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront
(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced the closing of its previously announced global collaboration agreement with Roche Holding AG (RHHBY) ...
MaxCyte enters technology license partnership with Genentech
MaxCyte (MXCT) announced that it has entered into a technology license partnership with Genentech, a member of Roche (RHHBY), to support the development of cell therapy programs. The license provides…
Roche Appoints Dan Malarek CEO Of Diagnostics North America; Names U.S. Commercial Chief
(RTTNews) - Roche Holding AG (RO.SW) announced the appointment of Dan Malarek as President and Chief Executive Officer of Roche Diagnostics North America, effective August 1, 2026. He succeeds Brad Mo...
Roche names Dan Malarek as President and CEO of Roche Diagnostics North America
Roche (RHHBY) announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective August 1. Malarek currently serves as Chief Executive Officer of Foundation Me...
Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America
Dan Malarek, current CEO of Foundation Medicine Inc., appointed President and CEO of Roche Diagnostics North America, effective August 1, 2026 Malarek succeeds Brad Moore, who will retire at the end o...
Roche (RHHBY) Receives FDA Priority Review for Gazyva Kidney Therapy Expansion
Roche (RHHBY) Receives FDA Priority Review for Gazyva Kidney Therapy Expansion
Genentech granted priority review for Gazyva sBLA by FDA
Genentech, a member of Roche (RHHBY), announced that the FDA has granted priority review to the company’s supplemental biologics license application, or sBLA, for Gazyva for the treatment of primary…
FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Appl...
FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has grant...
Roche Introduces First Fully Automated Hepatitis D Virus Test
(RTTNews) - Roche (RHHBY) has launched the cobas Hepatitis D Virus test, the first fully automated diagnostic solution to detect and quantify HDV RNA. The assay runs on Roche's cobas 5800/6800/8800 sy...
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
Basel, 14 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it introduces the cobas® HDV test for use on the cobas® 5800/6800/8800 systems, a diagnostic tool for the detection and qu...
Ionis Pharmaceuticals (IONS) Shares Drop After Roche Discontinues Trials
Ionis Pharmaceuticals (IONS) Shares Drop After Roche Discontinues Trials
Nurix Posts Wider Q2 Net Loss As Revenue Drops; Highlights $700 Mln Roche Deal
(RTTNews) - Nurix Therapeutics, Inc. (NRIX) reported financial results for the second quarter ended May 31, 2026, reflecting a wider net loss and a decline in revenue. In addition, the company provide...
Nurix (NRIX) Reports Q2 Revenue Miss, Highlights Roche Collaboration
Nurix (NRIX) Reports Q2 Revenue Miss, Highlights Roche Collaboration
Roche receives CE Mark for blood test to identify tuberculosis infection
Roche (RHHBY) announced that its Elecsys IGRA TB test has received the CE Mark, introducing a new blood testing solution for identifying tuberculosis infection in routine laboratory settings. “The new...
Roche Secures CE Mark For Automated Elecsys IGRA TB Diagnostic Test
(RTTNews) - Roche (RHHBY) announced that it has received the CE Mark for its Elecsys Interferon Gamma Release Assay (IGRA) TB test, a blood-based diagnostic test for identifying tuberculosis infection...
Roche receives CE Mark for blood test to identify tuberculosis infection
Basel, 9 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys IGRA TB test has received the CE Mark, introducing a new blood testing solution for identifying tuberculosis in...
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Roche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Basel, 7 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data from its Alzheimer's disease portfolio at the Alzheimer's Association International Conference® 20...
Genentech and Roche Present New Data in Alzheimer's Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data from its Alzheimer's disease...
Astex Enters Exclusive Collaboration With Genentech For Breast Cancer Therapy Program
(RTTNews) - Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., has announced an exclusive, worldwide research collaboration and license agreement with Genentech, a mem...
Roche downgraded to Hold from Buy at HSBC
HSBC downgraded Roche (RHHBY) to Hold from Buy with an unchanged price target of CHF 365. Vabysmo momentum might support the shares in the short-term as U.S. funding problems ease,…
Roche's (RHHBY) Divarasib Surpasses Competitors in Lung Cancer Trial
Roche's (RHHBY) Divarasib Surpasses Competitors in Lung Cancer Trial